目的:“头皮瘙痒对西班牙皮肤科会诊的影响:SCALP-PR试验”的启动是为了解决皮肤科头皮瘙痒这一常见但经常检查不充分的问题。这种情况导致无法控制的刮擦冲动,影响患者的生活质量,并可能导致头皮损伤。本研究旨在探讨患病率,患者简介,潜在的条件,以及在西班牙治疗头皮瘙痒的方法,并评估安全性和有效性,以及非药物治疗的耐受性。
方法:从2021年到2022年,75名皮肤科医生在一项关于头皮瘙痒的研究中招募了359名患者,Bellvitge大学医院研究伦理委员会批准,巴塞罗那,西班牙。这项基于证据的研究将荟萃分析与观察性研究技术相结合,专注于现实世界的证据,以检查治疗对生活质量(QoL)的影响。利用皮肤病生活质量指数(DLQI)进行QoL评估,该研究评估了该外用产品在15天内的有效性.通过eCRF进行数据收集,并用统计学方法进行分析,以提供对头皮瘙痒管理的可靠见解。
结果:发现西班牙头皮瘙痒的患病率为6.9%,主要在平均年龄为52.5岁的女性中。确定的主要原因是脂溢性皮炎和病因不明或敏感头皮瘙痒。压力被认为是一个关键因素,皮质类固醇和卫生措施是常见的治疗方法。在15天后,局部产品在超过90%的患者中显示出瘙痒和抓挠的显著减少。皮肤病生活质量也有所改善,87.1%的患者显示DLQI评分增强。该产品因其化妆品特性而广受好评,具有很高的纹理评级,易于应用,和香味。
结论:所研究的外用产品是安全的,有效,和美观的治疗,改善大多数患者的各种病因的头皮瘙痒。结果强调了皮肤科对患者中心治疗的需求,为临床实践和未来研究提供重要见解。
OBJECTIVE: The \"Impact of scalp pruritus in dermatological consultations in Spain: The SCALP-PR trial\" was initiated to address the common yet often insufficiently examined issue of scalp pruritus in dermatology. This condition leads to an uncontrollable urge to scratch, affecting the patients\' quality of life and potentially causing scalp damage. This study aimed to explore the prevalence, patient profile, underlying conditios, and therapeutic approaches for scalp pruritus in Spain, and to assess the safety and efficacy profile, as well as the tolerability of a non-pharmacologic treatment.
METHODS: From 2021 through 2022, 75 dermatologists enrolled a total of 359 patients in a study on scalp pruritus, approved by the Bellvitge University Hospital Research Ethics Committee, Barcelona, Spain. This evidence-based research combined a meta-analysis with observational study techniques focused on real-world evidence to examine the therapeutic impact on quality of life (QoL). Utilizing the Dermatology Life Quality Index (DLQI) for QoL assessments, the study evaluated the effectiveness of the topical product over 15 days. Data collection was conducted via an eCRF and analyzed with statistical methods to provide reliable insights into the management of scalp pruritus.
RESULTS: The prevalence of scalp pruritus in Spain was found to be 6.9%, predominantly among women with a mean age of 52.5 years. The leading causes identified were seborrheic dermatitis and pruritus of undetermined etiology or sensitive scalp. Stress was noted as a key factor, with corticosteroids and hygienic measures being common therapies. The topical product demonstrated significant reductions in pruritus and scratching in more than 90% of patients after 15 days. Improvements were also seen in dermatological quality of life, with 87.1% of patients showing enhancements in DLQI scores. The product was well-received thanksto its cosmetic properties, with high ratings in texture, ease of application, and fragrance.
CONCLUSIONS: The topical product studied is a safe, effective, and cosmetically appealing treatment, improving scalp pruritus in various etiologies for most patients. The results highlight the need for patient-center treatments in dermatology, providing important insights for clinical practice and future research.